BR0014222A - Método e composições para inibir a formação de adesão - Google Patents

Método e composições para inibir a formação de adesão

Info

Publication number
BR0014222A
BR0014222A BR0014222-0A BR0014222A BR0014222A BR 0014222 A BR0014222 A BR 0014222A BR 0014222 A BR0014222 A BR 0014222A BR 0014222 A BR0014222 A BR 0014222A
Authority
BR
Brazil
Prior art keywords
compositions
adhesion formation
inhibiting
inhibiting adhesion
methods
Prior art date
Application number
BR0014222-0A
Other languages
English (en)
Portuguese (pt)
Inventor
David A Cheresh
Bruce Lessey
Original Assignee
Scripps Research Inst
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Univ North Carolina filed Critical Scripps Research Inst
Publication of BR0014222A publication Critical patent/BR0014222A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/045—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0014222-0A 1999-09-23 2000-09-22 Método e composições para inibir a formação de adesão BR0014222A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40552299A 1999-09-23 1999-09-23
PCT/US2000/026095 WO2001021196A1 (en) 1999-09-23 2000-09-22 Method and compositions for inhibiting adhesion formation

Publications (1)

Publication Number Publication Date
BR0014222A true BR0014222A (pt) 2003-02-25

Family

ID=23604048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014222-0A BR0014222A (pt) 1999-09-23 2000-09-22 Método e composições para inibir a formação de adesão

Country Status (9)

Country Link
EP (1) EP1223962A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003509468A (cg-RX-API-DMAC7.html)
KR (1) KR20020048941A (cg-RX-API-DMAC7.html)
CN (1) CN1399554A (cg-RX-API-DMAC7.html)
AU (1) AU781442B2 (cg-RX-API-DMAC7.html)
BR (1) BR0014222A (cg-RX-API-DMAC7.html)
CA (1) CA2384812A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02003079A (cg-RX-API-DMAC7.html)
WO (1) WO2001021196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2025685T3 (da) 2007-08-15 2013-09-02 Canadian Blood Services Monoklonale antistoffer mod BETA3-integriner.
CA3030111C (en) 2016-07-13 2025-07-08 Mochida Pharmaceutical Co., Ltd. COMPOUND PREVENTING ADHESION
CN111936175A (zh) * 2018-01-15 2020-11-13 持田制药株式会社 防粘连用组合物
KR102318958B1 (ko) * 2019-08-08 2021-10-27 고려대학교 산학협력단 인테그린 α2β1 억제제를 유효성분으로 포함하는 조직 유착 예방 또는 치료용 약제학적 조성물
WO2021202643A1 (en) * 2020-03-31 2021-10-07 The Regents Of The University Of California Compositions and methods for treating dysregulated wound healing

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
AU8918898A (en) * 1997-08-25 1999-03-16 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibi tors

Also Published As

Publication number Publication date
WO2001021196A1 (en) 2001-03-29
JP2003509468A (ja) 2003-03-11
AU7985000A (en) 2001-04-24
EP1223962A4 (en) 2004-01-21
CA2384812A1 (en) 2001-03-29
AU781442B2 (en) 2005-05-26
MXPA02003079A (es) 2004-04-21
CN1399554A (zh) 2003-02-26
EP1223962A1 (en) 2002-07-24
KR20020048941A (ko) 2002-06-24

Similar Documents

Publication Publication Date Title
AR023130A1 (es) Composiciones para promover el crecimiento
EP1140964A4 (en) CONNECTIVE TISSUE GROWTH FACTOR FRAGMENTS, METHODS AND CORRESPONDING USES THEREOF
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BR9714415A (pt) Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE273690T1 (de) Zusammensetzung zur hautdesinfizierung
DE50010115D1 (de) Zusammensetzung und verfahren zur entkeimung von luft
BRPI0414918A (pt) compostos de benzoimidazola
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0607009A2 (pt) stent endoureteral absorvìvel composto reforçada com fibra
BR9811923A (pt) Compostos possuindo atividade neuronal
ATE293691T1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
BRPI0406596A (pt) Métodos para tratar a dor articular e melhorar o sono utilizando um agonista/antagonista de estrogênio
DE60138552D1 (de) Peptide mit integrinbindungsmotiv und behandlungsmethoden für muskelkrankheiten
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
TW200603746A (en) Iron sulfate based phosphate adsorbent
DE602004025265D1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
BR0308584A (pt) Composição farmacêutica androgênica e método para tratamento de depressão
DE69825901D1 (de) Vitamin e enthaltende plastikzusammensetzung für medizinische behälter und methoden zur bereitstellung solcher zusammensetzungen und behälter
ATE230414T1 (de) Mimetika von beta-faltblatt und verfahren zur verwendung davon
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
AU2003251728A8 (en) Placental growth factor as a target for the treatment of osteoporosis
BR9810996A (pt) Composição farmacêutica

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.